CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 98 enrolled
Drug / intervention
LBL-007 Injection +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05516914
NCT05516914Phase 2Completed
CompareCT.gov

A Multicenter Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LBL-007 in Combination With Tislelizumab in the Treatment of Malignancies

Nanjing Leads Biolabs Co.,Ltd·interventional·Posted Aug 26, 2022·Updated Apr 1, 2026

In Brief

A Phase 2 clinical trial evaluating LBL-007 Injection, Tislelizumab Injection, and 3 other interventions for Malignant Tumors. Completed, enrolled 98 participants across 15 sites.

Detailed Summary

This trial is an open and multicenter phase Ib/II clinical study, which aims to evaluate the safety, tolerability, PK characteristics, immunogenicity, and effectiveness.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMalignant Tumors
CountriesChina
Collaborators--

Timeline

Phase 2CompletedFinished
2023202420252026
First PostedAug 26, 2022
Enrollment StartSep 1, 2022
Primary CompletionJan 30, 2026
TodayJul 1, 2026
Enrollment to primary: 3.4 yearsPosted 3.8 years ago

Interventions

LBL-007 Injectiondrug

Initial dose - MTD; Q3W; intravenous infusion

Tislelizumab Injectiondrug

Initial dose; Q3W; intravenous infusion

Cisplatin Injectiondrug

Initial dose；Q3W; intravenous infusion

Gemcitabine Hydrochloride for Injectiondrug

Initial dose；Q3W; intravenous infusion

Docetaxel injectiondrug

Initial dose；Q3W; intravenous infusion